Business Description
Crism Therapeutics Corp
ISIN : VGG042401007
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.2 | |||||
3-Year EPS without NRI Growth Rate | 13.3 | |||||
3-Year FCF Growth Rate | 6.1 | |||||
3-Year Book Growth Rate | -48.1 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.56 | |||||
Quick Ratio | 6.56 | |||||
Cash Ratio | 5.3 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -3.29 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 6303.23 | |||||
Net Margin % | 24035.48 | |||||
FCF Margin % | 3628.21 | |||||
ROE % | -250.79 | |||||
ROA % | -181.01 | |||||
ROIC % | -564.2 | |||||
ROC (Joel Greenblatt) % | -2760 | |||||
ROCE % | -55.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.51 | |||||
Price-to-Tangible-Book | 1.59 | |||||
EV-to-EBIT | -0.75 | |||||
EV-to-EBITDA | -0.75 | |||||
EV-to-Revenue | -40.06 | |||||
EV-to-FCF | -1.11 | |||||
Price-to-Net-Current-Asset-Value | 1.59 | |||||
Price-to-Net-Cash | 1.9 | |||||
Earnings Yield (Greenblatt) % | -133.33 | |||||
FCF Yield % | -35.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AMMCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Crism Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | -0.039 | ||
EPS (TTM) ($) | -1.084 | ||
Beta | 0.29 | ||
Volatility % | 116.49 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 6.768 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 6.768 - 6.768 | ||
Shares Outstanding (Mil) | 32.68 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Crism Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Crism Therapeutics Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Crism Therapeutics Corp Frequently Asked Questions
What is Crism Therapeutics Corp(AMMCF)'s stock price today?
When is next earnings date of Crism Therapeutics Corp(AMMCF)?
Does Crism Therapeutics Corp(AMMCF) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |